Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir

BACKGROUND AND AIM: Loss of hepatitis B surface antigen (HBsAg) is an important goal in the treatment of chronic hepatitis B. We investigated whether switching from long‐term entecavir (ETV) administration to tenofovir (TFV) (tenofovir alafenamide [TAF] or tenofovir disoproxil fumarate [TDF]) could...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamaki, Nobuharu, Kurosaki, Masayuki, Kirino, Sakura, Yamashita, Koji, Osawa, Leona, Sekiguchi, Shuhei, Hayakawa, Yuka, Wang, Wan, Okada, Mao, Higuchi, Mayu, Takaura, Kenta, Maeyashiki, Chiaki, Kaneko, Shun, Yasui, Yutaka, Tsuchiya, Kaoru, Nakanishi, Hiroyuki, Itakura, Jun, Takahashi, Yuka, Enomoto, Nobuyuki, Izumi, Namiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273717/
https://www.ncbi.nlm.nih.gov/pubmed/32514449
http://dx.doi.org/10.1002/jgh3.12273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273717/
https://www.ncbi.nlm.nih.gov/pubmed/32514449
http://dx.doi.org/10.1002/jgh3.12273

Ejemplares similares